Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IRONWOOD PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for IRONWOOD PHARMACEUTICALS INC

IRWD

IRONWOOD PHARMACEUTICALS INC

About IRONWOOD PHARMACEUTICALS INC

Ironwood Pharmaceuticals is a biotech company focused on developing and commercializing gastrointestinal and rare disease therapies. Its flagship product, LINZESS, treats IBS-C and CIC globally through strategic partnerships. The company advances innovative pipeline candidates like apraglutide for short bowel syndrome and explores treatments for visceral pain conditions. Ironwood leverages its expertise in GI to bring life-changing medicines to patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IRONWOOD PHARMACEUTICALS INC

1
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports 159% Revenue Increase to $106.5 Million in Latest Quarter

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports $296.2 Million Revenue for Fiscal Year 2025, Down from $351.4 Million in 2024

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports 33.3% Revenue Growth to $122.1 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports Q2 2025 Financial Results with $23.6M Net Income

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports Significant Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports $351.4M Revenue for Fiscal Year 2024, Down from $442.7M in 2023

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
IRONWOOD PHARMACEUTICALS INC Ironwood Pharmaceuticals Reports Decline in Revenues and Net Income in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments